Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...108109110111112113114115116117118...858859»
  • ||||||||||  Vectibix (panitumumab) / Amgen, Takeda, Lumakras (sotorasib) / Amgen
    A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer. (Level 1, West Hall; Poster Bd # H13) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_774;    
    P1/2
    The toxicities of sotorasib plus panitumumab were consistent with the expected safety profile of the individual agents and with that reported previously for this combination; the ORR was similar to that previously observed for this combination in a more chemorefractory population. The ORR and PFS of sotorasib plus panitumumab compare favorably to current standard approaches in the 2L treatment of metastatic colorectal cancer.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival (OSERO study). (Level 1, West Hall; Poster Bd # G7) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_749;    
    Moreover, patients with RAS wild type of CRC would be more beneficial for this combination treatment. Clinical Trial Registration Number UMIN000040586 Sponsored by No funding sources reported Background: Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) are widely used as a later-line treatment for patients (pts) with metastatic colorectal cancer (mCRC)...The key eligibility criteria were ECOG performance status (PS) 0 or 1, pts refractory to or intolerant of fluoropyrimidine, oxaliplatin, irinotecan, anti
  • ||||||||||  Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
    FOLFOXIRI  (Level 1, West Hall; Poster Bd # G3) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_745;    
    Clinical Trial Registration Number UMIN000040586 Sponsored by No funding sources reported Background: Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) are widely used as a later-line treatment for patients (pts) with metastatic colorectal cancer (mCRC)...The key eligibility criteria were ECOG performance status (PS) 0 or 1, pts refractory to or intolerant of fluoropyrimidine, oxaliplatin, irinotecan, anti Based on these results, FOLFOXIRI
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States. (Level 1, West Hall; Poster Bd # E6) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_710;    
    Adults ?18 years old with ?1 claim for enco (first claim for enco on/after 4/1/2020) with concurrent cetux, as approved, or with EGFR panitumumab (pani), ?2 ICD-9/10 codes for malignancy of the colon or rectum ?30 days apart in the 1 year before index date, and ?1 day of pharmacy and medical continuous enrollment during the index date were included...Among the enco patients who had a previous treatment computed in claims, FOLFOX +/- bevacizumab (beva) and FOLFIRI + beva were the most common. This study provides current RW demographics, disease characteristics and treatment patterns among BRAF mCRC patients treated with enco in the US.
  • ||||||||||  Avastin (bevacizumab) / Roche, ME-344 / MEI
    A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer. (Level 1, West Hall; Poster Bd # N10) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_635;    
    P1/2
    This is an open-label phase 1b study in patients ?18 years old with metastatic colorectal cancer after failure of standard therapies, including fluoropyrimidine-, irinotecan-, and oxaliplatin-based regimens, anti-EGFR if RAS wild-type, PD/L-1-blocking antibody if MSI-H/dMMR, and BRAF-targeted therapy if BRAF V600E mutated...The study is actively enrolling, funded by MEI Pharma, and registered under NCT02100007. Clinical trial information: NCT02100007.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma. (Poster Bd # E16) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_468;    
    We evaluated the lifetime cost-effectiveness of a sequence of treatment with sorafenib followed by regorafenib (SOR-REG) compared with licensed single-line therapies for which there is no clear sequencing options available, including atezolizumab plus bevacizumab (ATEZO+BEV), which has become the standard of care in first-line treatment, as well as lenvatinib (LEN), followed by best supportive care (BSC). A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of
  • ||||||||||  Review, Journal:  An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults. (Pubmed Central) -  Dec 6, 2023   
    Some monoclonal antibodies, such as dupilumab (anti-IL-4?R?) and tralokinumab (anti-IL13) are already approved for the treatment of moderate-to-severe atopic dermatitis, and numerous articles in the literature have demonstrated their efficacy and safety...Data from phase 2b and phase III clinical trials in moderate-to-severe atopic dermatitis in adults indicate that these drugs have a promising efficacy and safety profile. Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Trial completion date, Trial primary completion date, IO biomarker, Surgery:  Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) -  Dec 6, 2023   
    P2,  N=40, Active, not recruiting, 
    Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Empaveli (pegcetacoplan SC) / Apellis, SOBI
    Review, Journal:  Targeting complement in IgA nephropathy. (Pubmed Central) -  Dec 6, 2023   
    Several ongoing trials are evaluating the efficacy of new agents against factor B (iptacopan, Ionis-FB-L), C3 (pegcetacoplan), factor D (vemircopan, pelecopan), C5 (ravulizumab, cemdisiran) and C5a receptor 1 (avacopan). In this study, we provide a comprehensive review of the role of complement in IgAN, including the emerging mechanisms of complement activation and the promising potential of complement inhibitors as a viable treatment option for IgAN.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Anti-CD19/CD8 bispecific T cell engager for the potential treatment of B cell malignancies. (Pubmed Central) -  Dec 6, 2023   
    The administration of blinatumomab was accompanied by several adverse effects, including activation of regulatory T-cells and cytokine storm...The ?CD8/CD19 bound to CD8and CD19cell lines and induced significant granzyme B production, cytotoxic activity and proliferation potential in the presence of IL-2 and tumor target cells. The maximum CD8T-cell biological activity was observed on the 10th day with 10:1 effector-to-target ratio.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Integration of Blinatumomab and Inotuzumab in Treatment of B-ALL (Stars at Night B4 (Ballroom Level, Henry B. Gonzalez Convention Center); in-person) -  Dec 5, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_432;    
  • ||||||||||  Jeselhy (pimitespib) / Otsuka
    Review, Journal, Stroma, Metastases:  Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors. (Pubmed Central) -  Dec 5, 2023   
    Common treatment-related adverse events were diarrhoea, decreased appetite, increase in serum creatinine, malaise, nausea and eye disorders. The efficacy and safety of pimitespib are being investigated in other tumour types and in combination with other anticancer therapies.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    New trial:  Effects of evolocumab on hemostasis in patients with primary membranous nephropathy (EUDRACT) -  Dec 5, 2023   
    P=N/A,  N=132, Not yet recruiting, 
    Further investigation of the long-term efficacy of CGRP-mAb for MOH is needed. .